NCT00486187View on ClinicalTrials.gov

Effects of ROSIglitazone on Inflammatory Markers and Adipokines in Diabetic Patients Using an Angiotensin Receptor Blocker (TELmisartan) - The ROSITEL Study

NACompletedINTERVENTIONAL
Enrollment

103

Participants

Timeline

Start Date

April 30, 2006

Primary Completion Date

June 30, 2009

Study Completion Date

June 30, 2009

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

rosiglitazone

DRUG

metformin or sulfonylurea

Trial Locations (1)

L6V 1B4

Partners Research, Brampton

Sponsors

Collaborators (1)

GlaxoSmithKline
All Listed Sponsors
collaborator

GlaxoSmithKline

INDUSTRY

lead

Dr. Milan Gupta

OTHER

NCT00486187 - Effects of ROSIglitazone on Inflammatory Markers and Adipokines in Diabetic Patients Using an Angiotensin Receptor Blocker (TELmisartan) - The ROSITEL Study | Biotech Hunter | Biotech Hunter